Drug Interactions of Daflon
Daflon (micronized purified flavonoid fraction) has no clinically significant drug interactions documented in the medical literature. The available evidence focuses exclusively on its pharmacological effects on venous tone, microcirculation, and inflammatory processes in chronic venous disease, with no reports of interactions with other medications 1, 2, 3.
Evidence Base for Safety Profile
No cytochrome P450 involvement: Unlike many medications that interact through CYP2C9, CYP3A4, or other cytochrome P450 pathways, Daflon's mechanism of action involves direct effects on venous wall tone, lymphatic drainage, and microcirculatory protection without hepatic enzyme metabolism 2, 4.
No P-glycoprotein interactions: The compound does not appear to function as a substrate, inhibitor, or inducer of P-glycoprotein transport systems, which are responsible for many significant drug interactions with anticoagulants and other cardiovascular medications 5.
Extensive clinical trial safety data: Multiple randomized controlled trials involving thousands of patients (including the RELIEF study with 5,052 patients) reported minimal side effects, with treatment withdrawal occurring in only 3 patients across studies, and no drug interaction-related adverse events documented 1, 3.
Clinical Implications
Safe for polypharmacy patients: Daflon can be prescribed to patients with chronic venous disease who are taking anticoagulants, antiplatelet agents, antihypertensives, or other cardiovascular medications without dose adjustments or additional monitoring 2, 5.
No monitoring requirements: Unlike warfarin or direct oral anticoagulants that require careful screening for CYP3A4 and P-gp interactions, Daflon does not necessitate baseline drug interaction screening or ongoing pharmacokinetic monitoring 4.
Combination therapy compatibility: The medication has been safely used in conjunction with compression therapy, sclerotherapy, and surgical interventions for venous disease without reported interactions 2, 5.